A 28-year-old woman with regular menses and no contraindications presents for contraceptive counseling. She has no history of migraine with aura, thromboembolism, or smoking. She prefers a combined oral contraceptive (COC) for its reliability and ease of use. Which is the drug of choice for first-line combined oral contraceptive therapy in this patient?

Explanation

## First-Line Combined Oral Contraceptive Selection ### Standard-Dose COC Formulation **Key Point:** Ethinyl estradiol (EE) 30 µg combined with levonorgestrel 150 µg is the most widely recommended first-line COC globally and in India, endorsed by WHO and NEET PG curricula. ### Why This Regimen? | Feature | EE 30 µg + LNG 150 µg | Rationale | |---------|----------------------|----------| | **Estrogen dose** | 30 µg (standard) | Balances efficacy and safety; minimizes VTE/stroke risk vs. older 50 µg formulations | | **Progestin** | Levonorgestrel (2nd gen) | Proven track record; excellent cycle control; minimal metabolic effects | | **Efficacy** | >99% with perfect use | Pearl Index ~0.1 | | **Side effects** | Minimal at this dose | Lower breakthrough bleeding than 20 µg formulations | | **Cost & availability** | Widely available in India | Generic formulations abundant; cost-effective | ### Clinical Pearl **High-Yield:** The 30 µg EE + LNG 150 µg combination is the **gold standard** first-line COC. It offers the optimal balance between contraceptive efficacy, cycle control, and tolerability. Lower-dose formulations (20 µg) are reserved for patients with specific risk factors (age >35, smoking, migraine with aura) or intolerance to standard-dose pills. ### Comparison with Other Options | Option | Why NOT first-line | |--------|-------------------| | **Estradiol valerate + dienogest** | Newer, more expensive; reserved for patients with specific needs (e.g., PCOS, acne); not standard first-line in resource-limited settings | | **Mestranol 50 µg + norethisterone** | Outdated; higher estrogen dose increases VTE and MI risk; mestranol has lower bioavailability than EE | | **EE 20 µg + desogestrel** | Ultra-low dose; higher breakthrough bleeding; reserved for older women or those with contraindications to standard dose | **Warning:** Do not confuse **first-line** (standard-dose 30 µg EE + LNG) with **individualized** choices. Tailoring depends on age, comorbidities, and side-effect profile. [cite:KD Tripathi 8e Ch 62]